A series of novel β-amino acids has been synthesized and tested for their in vitro antifungal activity against Candida albicans. A steep SAR was observed. β-Amino acid 21 (BAY 10- 8888/PLD-118) revealed the most favourable activity–tolerability profile and was selected for clinical studies as a novel antifungal for the oral treatment of yeast infections.